Protalix BioTherapeutics
PLX
PLX
36 hedge funds and large institutions have $3.4M invested in Protalix BioTherapeutics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
24% less capital invested
Capital invested by funds: $4.46M → $3.4M (-$1.06M)
50% less call options, than puts
Call options by funds: $17K | Put options by funds: $34K
Holders
36
Holding in Top 10
–
Calls
$17K
Puts
$34K
Top Buyers
| 1 | +$131K | |
| 2 | +$51.2K | |
| 3 | +$31.6K | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$18K |
| 5 |
VF
Virtu Financial
New York
|
+$10K |
Top Sellers
| 1 | -$187K | |
| 2 | -$68.8K | |
| 3 | -$42.9K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$38.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35.5K |